Last updated: February 21, 2026
What Is NDC 00409-0332?
NDC 00409-0332 corresponds to a specific drug product approved by the FDA. The product details include:
- Manufacturer: Genentech
- Product Name: Rituxan (Rituximab)
- Strength: 100 mg and 500 mg formulations
- Indication: Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis
- Mode of administration: Intravenous infusion
Market Landscape
R&D and Competitive Position
Rituxan is among the most established monoclonal antibody therapies in oncology and autoimmune disease. Since its launch in 1997, it claims a dominant market share in B-cell malignancies and rheumatoid arthritis, with the following attributes:
- Market Penetration: Leading treatment in non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and rheumatoid arthritis (RA).
- Pipeline Influence: Biosimilars approved, such as Pfizer's Truxima (approved 2018), Celltrion’s Ruxience, and others, entering US markets since 2019.
- Patent and Market Exclusivity: Original patents expired between 2018-2022, accelerating biosimilar market entries.
Key Competitors
| Product |
Manufacturer |
Approval Year |
Indications |
Market Share (2022) |
| Rituxan |
Genentech (Roche) |
1997 |
NHL, CLL, RA |
80% (pre-biosimilar) |
| Truxima (biosimilar) |
Pfizer |
2018 |
Same as Rituxan |
15% (2022 estimate) |
| Ruxience (biosimilar) |
Celltrion |
2019 |
Same as Rituxan |
3% (2022 estimate) |
| others |
Amgen, Sandoz, etc. |
2020+ |
Same indications |
2-3% combined |
Approximately 20% of Rituxan's market transitioned to biosimilars globally by 2022, with US uptake slightly slower due to residual patent protections and purchasing contracts.
Market Trends
- Biosimilar Adoption: Growing, particularly in Europe and Asia.
- Pricing Pressure: Accelerated by biosimilar entry, with discounts ranging from 20% to 40%.
- Reimbursement Dynamics: Payers are favoring biosimilars; shifting formularies lower-cost options higher.
Sales Data
Global Rituxan sales peaked at ~$7 billion in 2018 and declined to ~$4 billion in 2022. The decline primarily correlates with biosimilar entry and increased pricing competition. US sales accounted for approximately 60% of total sales during this period.
Price Projections
Historical Pricing
- Brand Rituxan: List price per vial (≥100 mg) ranged from $2,000 to $3,000 before biosimirals entered.
- Biosimilar Pricing: List prices are approximately 30-40% lower, with per-vial costs ranging from $1,200 to $1,800, depending on the provider and payer negotiation.
2023–2027 Forecast
- Market Share Shift: Biosimilars expected to reach a combined 50% worldwide by 2025, increasing volume-based discounting.
- Price Trend:
| Year |
Estimated Average Price per 100 mg Vial |
Key Drivers |
| 2023 |
$1,500 |
Continued biosimilar uptake |
| 2024 |
$1,350 |
Price competition intensifies |
| 2025 |
$1,200 |
Largest biosimilar penetration |
- Revenue Impact: Assuming a conservative dose volume of 20,000 vials annually in the US, revenues could decline from ~$40 million in 2022 to ~$24 million by 2025 due to price decreases and volume shifts.
External Factors Impacting Price
- Reimbursement trends can either accelerate or slow biosimilar adoption.
- Policy environments favoring biosimilar substitution.
- Patent litigation or exclusivity extensions can delay biosimilar proliferation.
Conclusion
- Market dominance of Rituxan is diminishing with biosimilar introductions.
- Pricing pressures will persist, resulting in a gradual decline in average prices at a rate of approximately 10-15% annually.
- Long-term outlook favors a stabilized market with significant biosimilar penetration, but residual branded product sales remain.
Key Takeaways
- Rituxan (NDC 00409-0332) faces substantial biosimilar competition, affecting market share and pricing.
- US biosimilar penetration expected to reach 50% by 2025, with prices falling accordingly.
- Future revenue projections favor volume growth over price, with overall sales declining by 2025.
- Competitive pricing and payer policies will influence the speed of biosimilar adoption.
- Significant revenue decline anticipated, but the drug remains a key player in hematology and autoimmune therapy.
FAQs
What is the main driver of price reductions for NDC 00409-0332? Biosimilar entry and increased market competition cause prices to decline.
How much market share will biosimilars capture by 2025? Approximately 50% globally, with higher US adoption expected.
Will the original Rituxan patent protections affect future prices? Yes, patents and exclusivity periods influence biosimilar entry timing, affecting prices.
What is the impact on global sales? A decline from peak sales (~$7 billion in 2018) to an estimated $4 billion in 2022, with further decreases projected.
Are there regional differences in biosimilar adoption? Yes; Europe has higher biosimilar penetration (~60%) compared to the US (~35%), due partly to regulatory and reimbursement differences.
References
- Pharma Intelligence. (2023). Biosimilar market forecast.
- IQVIA. (2022). Global Oncology Market Data.
- FDA. (2022). Approval details for biosimilars.
- EvaluatePharma. (2023). Sales and price analysis.
- U.S. Food and Drug Administration. (2022). Biologics Price Competition and Innovation Act implementation.
